MG217 Treatment Cream and Skin Protectant Recalled Due to Staphylococcus Aureus Contamination

Key Takeaways:

• The US Food and Drug Administration (FDA) has issued a voluntary Class I recall for MG217 multisymptom treatment cream and skin protectant. The affected batch has been identified as Lot 1024088 (expires November 2026), affecting 690 tubes.
• The recall was initiated by Wisconsin Pharmacal Company due to microbial contamination of staphylococcus aureus, a quality issue that may cause serious adverse health consequences or death.
• MG217 cream is used to treat symptoms of psoriasis and seborrheic dermatitis.

The FDA has issued a Class I recall for MG217 multisymptom treatment cream and skin protectant, affecting 690 tubes. This medication is being recalled by Wisconsin Pharmacal Company based in Jackson, Wisconsin. The recall was initiated on April 24, 2026, and received a Class I classification on May 29, 2026. A Class I classification means the use of this product may cause serious adverse health consequences or death.

The recall was initiated due to staphylococcus aureus contamination, specifically for Lot 1024088, which will expire in November 2026. Wisconsin Pharmacal Company sent out a public notice via letter, and a public press release was issued on May 8, 2026.

MG217 cream is an over-the-counter medication used to relieve skin irritation, redness, and itching caused by psoriasis and seborrheic dermatitis. Pharmacists should identify and quarantine Lot 1024088, remove it from inventory, and coordinate with prescribers to provide an alternative supply.

Reference

FDA. Enforcement Report. May 27, 2026. Accessed June 3, 2026. https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=219834